Trial Profile

Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Subjects With Advanced Gastrointestinal Stromal Tumor

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 21 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DS-6157 (Primary)
Indications Gastrointestinal stromal tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Daiichi Sankyo Inc

Most Recent Events

14 Feb 2024 Status changed from completed to discontinued.
07 Jun 2022 As per the results presented at the 58th Annual Meeting of the American Society of Clinical Oncology, the study did not proceed to Part 2, because the data from Part 1 did not meet efficacy targets.
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com